These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28893780)

  • 1. Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.
    Forrest A; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Paterson DL; Li J; Silveira FP; Nation RL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28893780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.
    Dalfino L; Puntillo F; Ondok MJ; Mosca A; Monno R; Coppolecchia S; Spada ML; Bruno F; Brienza N
    Clin Infect Dis; 2015 Dec; 61(12):1771-7. PubMed ID: 26354965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing guidance for intravenous colistin in critically-ill patients.
    Nation RL; Garonzik SM; Thamlikitkul V; Giamarellos-Bourboulis EJ; Forrest A; Paterson DL; Li J; Silveira FP
    Clin Infect Dis; 2017 Mar; 64(5):565-571. PubMed ID: 28011614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.
    Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT
    J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
    Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.
    Durante-Mangoni E; Andini R; Signoriello S; Cavezza G; Murino P; Buono S; De Cristofaro M; Taglialatela C; Bassetti M; Malacarne P; Petrosillo N; Corcione A; Viscoli C; Utili R; Gallo C
    Clin Microbiol Infect; 2016 Dec; 22(12):984-989. PubMed ID: 27545697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy.
    Ozel AS; Ergönül Ö; Korten V
    J Infect Dev Ctries; 2019 Oct; 13(10):877-885. PubMed ID: 32084017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute kidney injury following colistin treatment in critically-ill patients: may glucocorticoids protect?
    Heybeli C; Canaslan K; Oktan MA; Yıldız S; Arda HÜ; Çavdar C; Çelik A; Gökmen N; Cömert B
    J Chemother; 2021 Apr; 33(2):85-94. PubMed ID: 32500843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
    Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study.
    Rocco M; Montini L; Alessandri E; Venditti M; Laderchi A; De Pascale G; Raponi G; Vitale M; Pietropaoli P; Antonelli M
    Crit Care; 2013 Aug; 17(4):R174. PubMed ID: 23945197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of a Colistin Loading Dose, High-Dose Maintenance Regimen in Critically Ill Patients With Multidrug-Resistant Gram-Negative Pneumonia.
    Elefritz JL; Bauer KA; Jones C; Mangino JE; Porter K; Murphy CV
    J Intensive Care Med; 2017 Sep; 32(8):487-493. PubMed ID: 27139010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
    Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
    Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates.
    Nakwan N; Usaha S; Chokephaibulkit K; Villani P; Regazzi M; Imberti R
    Pediatr Infect Dis J; 2016 Nov; 35(11):1211-1214. PubMed ID: 27276179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin.
    Ko Hj; Jeon Mh; Choo Ej; Lee Ej; Kim Th; Jun JB; Gil HW
    Nephron Clin Pract; 2011; 117(3):c284-8. PubMed ID: 20847571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.